Patent ID: 9713644
Date: 2017-07-25
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of treating an inflammatory disease comprising administering to a patient in need thereof an isolated monovalent antagonistic anti-DR3 antibody, wherein the antibody comprises a heavy chain variable region comprising a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3; wherein the antibody comprises a light chain variable region comprising a light chain CDR1, a light chain CDR2, and a light chain CDR3; wherein the heavy chain CDR1 comprises an amino acid sequence corresponding to Kabat residues 31-35 of SEQ ID NO:10, the heavy chain CDR2 comprises an amino acid sequence corresponding to Kabat residues 50-58 of SEQ ID NO:10, and the heavy chain CDR3 comprises an amino acid sequence corresponding to Kabat residues 95-102 of SEQ ID NO:10; and wherein the light chain CDR1 comprises an amino acid sequence corresponding to Kabat residues 24-34 of SEQ ID NO:11, the light chain CDR2 comprises an amino acid sequence corresponding to Kabat residues 50-56 of SEQ ID NO:11, and the light chain CDR3 comprises an amino acid sequence corresponding to Kabat residues 89-97 of SEQ ID NO:11.